Roles of Vascular Endothelial Growth Factor in Amyotrophic Lateral Sclerosis

الملخص EN

Amyotrophic lateral sclerosis (ALS) is a fatal devastating neurodegenerative disorder, involving progressive degeneration of motor neurons in spinal cord, brainstem, and motor cortex.

Riluzole is the only drug approved in ALS but it only confers a modest improvement in survival.

In spite of a high number of clinical trials no other drug has proved effectiveness.

Recent studies support that vascular endothelial growth factor (VEGF), originally described as a key angiogenic factor, also plays a key role in the nervous system, including neurogenesis, neuronal survival, neuronal migration, and axon guidance.

VEGF has been used in exploratory clinical studies with promising results in ALS and other neurological disorders.

Although VEGF is a very promising compound, translating the basic science breakthroughs into clinical practice is the major challenge ahead.

VEGF-B, presenting a single safety profile, protects motor neurons from degeneration in ALS animal models and, therefore, it will be particularly interesting to test its effects in ALS patients.

In the present paper the authors make a brief description of the molecular properties of VEGF and its receptors and review its different features and therapeutic potential in the nervous system/neurodegenerative disease, particularly in ALS.